Market DemandA notable 7 in 10 smokers want to quit, indicating a strong market demand for effective cessation aids.
Product EfficacyCytisinicline demonstrated a clinical benefit in smoking cessation with a good tolerability profile in two Phase III trials (ORCA-2 and -3). Cytisinicline was superior to placebo and to current smoking cessation options.
Regulatory ProgressThe company has successfully collected long-term safety data for cytisinicline, fulfilling a key NDA submission requirement for smoking cessation.